Literature DB >> 8976708

Local interferon alfa-2b for ocular cicatricial pemphigoid.

M Gillies, I Francis, P McCluskey, D Wakefield.   

Abstract

Mesh：

Substances：

Year:  1996        PMID： 8976708      PMCID： PMC505653          DOI： 10.1136/bjo.80.10.927

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN： 0007-1161            Impact factor:   4.638


× No keyword cloud information.
  6 in total

1.  Ocular cicatricial pemphigoid.

Authors:  I C Francis; P J McCluskey; R S Walls; D Wakefield; J M Brewer
Journal:  Aust N Z J Ophthalmol       Date:  1990-05

Review 2.  The role of cytokines in the pathogenesis of inflammatory eye disease.

Authors:  D Wakefield; A Lloyd
Journal:  Cytokine       Date:  1992-01       Impact factor: 3.861

3.  Interferon-alpha 2b enhances barrier function of bovine retinal microvascular endothelium in vitro.

Authors:  M C Gillies; T Su
Journal:  Microvasc Res       Date:  1995-05       Impact factor: 3.514

Review 4.  Cytokines, fibrosis and the failure of glaucoma filtration surgery.

Authors:  M C Gillies; T Su
Journal:  Aust N Z J Ophthalmol       Date:  1991-11

5.  Foreshortening of the inferior conjunctival fornix associated with chronic glaucoma medications.

Authors:  I R Schwab; J V Linberg; V M Gioia; W H Benson; G M Chao
Journal:  Ophthalmology       Date:  1992-02       Impact factor: 12.079

6.  Immunosuppressive therapy in ocular cicatricial pemphigoid.

Authors:  B J Mondino; S I Brown
Journal:  Am J Ophthalmol       Date:  1983-10       Impact factor: 5.258
  6 in total
  2 in total

Review 1.  Interferon associated retinopathy.

Authors:  S Hayasaka; Y Nagaki; M Matsumoto; S Sato
Journal:  Br J Ophthalmol       Date:  1998-03       Impact factor: 4.638

2.  European guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology - Part I.

Authors:  H Rashid; A Lamberts; L Borradori; S Alberti-Violetti; R J Barry; M Caproni; B Carey; M Carrozzo; F Caux; G Cianchini; A Corrà; G F H Diercks; F G Dikkers; G Di Zenzo; C Feliciani; G Geerling; G Genovese; M Hertl; P Joly; A V Marzano; J M Meijer; V Mercadante; D F Murrell; M Ormond; H H Pas; A Patsatsi; C Prost; S Rauz; B D van Rhijn; M Roth; E Schmidt; J Setterfield; G Zambruno; D Zillikens; B Horváth
Journal:  J Eur Acad Dermatol Venereol       Date:  2021-07-10       Impact factor: 6.166
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.